61Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Greece
Neuroscience Intelligence
Greece neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #27 of 50 · Data maturity A · Research score 34.5 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
27Recruiting trials
51Publications
52Institutions
Executive interpretation
Greece ranks #27 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC87 recruiting
Novo Nordisk A/S40 recruiting
Aristotle University Of Thessaloniki31 recruiting
National and Kapodistrian University of Athens32 recruiting
Hoffmann-La Roche22 recruiting
Attikon Hospital21 recruiting
Boehringer Ingelheim20 recruiting
AbbVie20 recruiting
Bayer22 recruiting
Eli Lilly and Company20 recruiting
Disease activity
Parkinsons9trials
Alzheimers8trials
Epilepsy6trials
Multiple Sclerosis6trials
Schizophrenia3trials
Stroke3trials
Autism2trials
Depression2trials
Other Psychiatry2trials
Migraine Headache1trials
Research institutions
University of PatrasOpenAlexlinked institution
Hellenic Cardiological SocietyOpenAlexlinked institution
Henry Dunant HospitalOpenAlexlinked institution
General University Hospital of PatrasOpenAlexlinked institution
Foundation for Research and Technology HellasOpenAlexlinked institution
Academy of AthensOpenAlexlinked institution
National and Kapodistrian University of AthensOpenAlexlinked institution
Ippokrateio General Hospital of ThessalonikiOpenAlexlinked institution
Aristotle University of ThessalonikiOpenAlexlinked institution
Institute of Communication and Computer SystemsOpenAlexlinked institution
Clinical evidence trail
NCT07672938Effects of Hydroxytyrosol-Rich Olive Polyphenol Dietary Supplement Combined With Mediterranean Diet Adherence on the Cognitive Health of Patients With Mild Cognitive ImpairmentRECRUITING
NCT07289061Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain FunctionRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07106632Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT07001449Effectiveness of Communication-Focused Pain Neuroscience Education in Chronic Musculoskeletal PainRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06903130Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)NOT_YET_RECRUITING
Research evidence trail
PUBMEDSaccadic eye movements based classification of patients with obsessive-compulsive disorder, patients with schizophrenia and healthy controls using artificial neural networks.2026-12-01
PUBMEDDentate gyrus immaturity and region-specific synaptic and autophagy alterations across hippocampal subfields in schizophrenia.2026-11-01
PUBMEDAlexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy.2026-11-01
PUBMEDPsychological Functioning and Parent-Child Mental Health Interrelations in Pediatric Gastrointestinal Autoimmune Disorders.2026-10-07
PUBMEDWhat shapes health-related quality of life in drug-resistant epilepsy? Clinical, emotional, and cognitive predictors.2026-10-05
PUBMEDEffects of High-Phenolic Extra Virgin Olive Oil on Sensory Processing in Children With Autism Spectrum Disorder: A Pilot Study.2026-10-01
PUBMEDTransdiagnostic determinants of Growth Differentiation Factor-15 (GDF-15) in psychiatric in-patients: age, renal indices, interleukin-6 (IL-6) and soluble urokinase plasminogen activator receptor (suPAR).2026-10-01
PUBMEDCerebral Lateralization for Language as a Potential Biomarker for the Broad Autism Phenotype: A Functional Transcranial Doppler Ultrasonography Investigation.2026-10-01
PUBMEDFear of death increases nocebo-prone behavior in people with headaches during covid-19. A longitudinal observational survey.2026-09-09
PUBMEDCross-Informant Agreement and Discrepancies in ADHD Assessment During Adolescence: A Systematic Review and Meta-Analysis.2026-09-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.